The evidence
As a biotech company leveraging next-generation sequencing and smart systems to identify pathogens and antimicrobial resistance and to assess clinical risk, the Biotia Team and our collaborators published clinical and research studies in the field of infectious disease diagnostics, microbial surveillance environmental metagenomics.
Clinical evidence
Published over 40 peer-reviewed studies driven by expertise of the Biotia Team and our collaborators globally focusing on clinical and environmental metagenomics, infectious disease diagnostics and microbial surveillance.
ID Week 2023: Utilization of Clinical-Grade Metagenomics in Urinary Tract Infection Diagnostics: Improving High-Risk Patients’ Outcomes with a Genomic-Based Assay
High-risk patients frequently harbor atypical pathogens leading to inaccurate SOC testing and ineffective therapeutics. Genomic-based diagnostics may improve accuracy of urogenital pathogen detection and offer physicians precision therapeutics with better health outcomes while enhancing antimicrobial stewardship.
ASM 2023: Highly Accurate and Reliable Next-Generation Sequencing-Based Urine Assay Overperforms Conventional Diagnostics
We have built and validated a clinical-grade sequencing-based pipeline that accurately identifies key pathogens in clinical urine samples using a machine learning classification approach.
Publications
The Challenges and Opportunities in Creating an Early Warning System for Global Pandemics (pre-print)
Ozone Disinfection for Elimination of Bacteria and Degradation of SARS-CoV2 RNA for Medical Environments
Comparative Effectiveness of Single vs Repeated Rapid SARS-CoV-2 Antigen Testing Among Asymptomatic Individuals in a Workplace Setting
Technical notes
Rapid Gastrointestinal (GI) PCR Testing
We offer The BioFire® FilmArray® Gastrointestinal (GI) Panel in our New York State CLIA laboratory in Brooklyn, NY. You can read more about this test on the BioFire website.The FilmArray GI is a multiplexed nucleic acid test intended for use with the FilmArray Instrument for the simultaneous qualitative detection and identification of nucleic acids from multiple bacteria, viruses, and parasites directly from stool samples in Cary Blair transport media obtained from individuals with signs and/or symptoms of gastrointestinal infection.
Rapid Respiratory PCR Testing
We offer respiratory testing for common infections including COVID-19 using the FDA-approved BioFire® RP2.1 Panel with SARS-CoV-2 at our NYS CLIA Laboratory. You can read more about this test on the BioFire website.The BioFire RP2.1 is a multiplexed nucleic acid test intended for the simultaneous qualitative detection and differentiation of nucleic acids from multiple viral and bacterial respiratory organisms, including nucleic acids from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Hybrid Capture Sequencing is More Robust than Amplicon Sequencing for Viral Surveillance
Our ability to intercept and combat new pandemic strains is contingent on robust and accurate technologies for viral genome sequencing. A common method for viral genome sequencing employs the polymerase chain reaction (PCR). This method is not robust over time when dealing with a rapidly mutating organism, as mutations can accumulate in amplicon primer binding regions, leading to drop-outs. Here we show that target capture sequencing is a robust alternative for pandemic strain surveillance that does not present dropouts in rapidly mutating strains.
Stay informed with Biotia
Sign up for our newsletter to stay up-to-date on the latest news and breakthroughs in infectious disease research, genomics, and AI-powered technology.
